Prognostic role of prostate specific antigen kinetics in primary high volume metastatic hormonal sensitive prostate cancer treated with novel hormonal therapy agents Authors: Yingchun Wang, Jie Suo, Bo Wang, Qunli Men, Dachuan Wang, Haibo Jing, Tao Li, Xiaodong Huang, Chenqing Wang, Xiaohui Luo, Yuquan Ju, Junjie Fan, Jianzhou Liu Published: 2024 ABSTRACT AbstractThe prognostic value of prostate-specific antigen (PSA) kinetics in primary high-volume metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with novel hormonal therapy agents is still unclear. Here, we retrospectively reviewed the data of 102 patients with primary high-volume mHSPC who received novel hormonal therapy agents. The median follow-up was 32.25 ± 14.51 months and the median nadir PSA (nPSA) was 0.20 (0.06, 11.71) ng/mL after treatment. The mean time to nPSA was 10.82 ± 7.27 months and 55 patients (53.9%) had a PSA-density (PSA-D) ≤ 0.08 at 3-months. Univariate and multivariate Cox regression analyses showed that the absence of visceral metastases, nPSA ≤ 0.2 and PSA-D ≤ 0.08 were independent prognostic factors for better PFS and OS (all P < 0.05). Moreover, patients with nPSA ≤ 0.2 and PSA-D ≤ 0.08 had the best PFS and OS, and the combination of the nPSA and PSA-D had a better predictive accuracy for PFS and OS than nPSA and PSA-D alone. Thus, Visceral metastases, nPSA and PSA-D were independent prognostic factors for primary high-volume mHSPC patients treated with novel hormonal therapy agents. Patients with lower nPSA and PSA-D had a best survival outcome, and the combination of nPSA and PSA-D had a better effect on prognosis predicting.Keywords: High-volume mHSPC, Novel hormonal therapy agents, Visceral metastases, PSA kinetics, PrognosisSubject terms: Prostate cancer, Cancer screening, Tumour biomarkers Introduction Prostate cancer (PCa) is the second most common cancer in men worldwide, with an estimated annual increase of nearly 1.4 million new cases1. Among new cases of PCa, approximately 6% of patients present with metastatic hormone-sensitive PCa (mHSPC) in the USA, and up to 68% in the China2,3. For decades, androgen deprivation therapy (ADT) was the standard of care for mHSPC. However, the treatment of mHSPC has been tremendously changed based on the convincing data of recent studies4, and upfront novel hormonal therapy agents, such as abiraterone acetate, enzalutamide, combined with ADT have become the new standard of care for primary mHSPC, especially for high-volume mHSPC5. While, not all high volume mHSPC patients had a good response to novel hormonal therapy agents and nearly all high volume mHSPC patients would eventually progress to castration-resistant disease which was associated with high morbidity and mortality. Thus, early identified patients who were at high risk of progression might been helpful to urologists to adjust treatment regimens and prolong survival for these patients. Prostate-specific antigen (PSA) is not only widely used for PCa screening, but also as a useful monitoring indicator for treatment efficacy in clinical practice. Previously, Tomioka et al. found that nadir PSA (nPSA) ≥ 0.2 ng/mL and a shorter time to nadir PSA was associated with inferior oncological outcomes in patients treated with ADT6. Subsequently, several studies also documented that PSA decline and progression were well-established prognostic factors for patients treated with ADT combined docetaxel7–9. In addition, PSA-density (PSA-D), represented a proportion of prostate tumor-derived PSA, also had modest prognostic value in PCa treated with conventional radiotherapy10,11. Thus, PSA kinetics, including nPSA, time to nPSA, PSA-D, were promising tool to predict the treatment efficacy and oncological outcomes in various clinical settings. However, there is a scarcity of published data on the association between PSA kinetics and oncological outcomes in high-volume mHSPC patients treated with new hormonal therapy agents. Herin, we retrospectively reviewed the clinicopathological characteristic of primary high-volume mHSPC patients who were treated with novel hormonal therapy agents and aimed to investigate the value of PSA kinetics in predicting survival outcomes. Methods Study population The data of patients who were primary diagnosed as high-volume mHSPC at our institute between January 2019 and July 2023 were retrospectively reviewed. The inclusion criteria were as follow: (1) meet the criteria of high-volume mHSPC in according to the CHAARTED criteria (presence of visceral metastases and/or ≥ four bone metastases with at least one outside of the vertebral column and pelvis)12; (2) primary diagnosed as mHSPC and treated with ADT combined with novel hormonal therapy agents. Patients were excluded if they had prior invasive malignancy, had any serious comorbidity, with incomplete data, and had previous treatment before ADT and novel hormonal therapy agents. All patients received pelvic multi-parameter magnetic resonance imaging (mp-MRI) followed by ultrasound (TRUS)-guided 12-core transrectal prostate biopsy and targeted biopsy was performed if suspicious lesions were found at mp-MRI13. Metastatic lesions were identified by conventional imaging (CI) examinations including chest and abdominal computerized tomography (CT), pelvic mp-MRI and Tc-99 m bone scintigraphy. This study was approved by the Institutional Review Board of the Baoji Central Hospital, Baoji, Shaanxi, P.R. China. All patients in this study provided written informed consent. PSA kinetics and outcome measures Patients were followed up every month for the first 3 months and every 3 months thereafter with PSA tests and CI examinations. The PSA measurements at screening before treatment were defined as initial PSA (iPSA). The nPSA was defined as the lowest PSA value post-treatment, and the time to nPSA was defined as the time from treatment beginning to nPSA. PSA90 responses describe ≥ 90% decline from baseline according to PCWG2 criteria. PSA-D was calculated at 3 months after treatment by dividing serum PSA by the MRI-derived prostate volume, and the optimal cutoff values of PSA-D were 0.08 ng/mL2 in consist with the previous reports14,15. In addition, the optimal cutoff values of the nPSA and time to nPSA were calculated by receiver operating characteristic (ROC) curves based on the largest Youden index. The optimal cut-off values of the nPSA and time to nPSA were 0.2 ng/mL and 10 months, respectively. The endpoint of survival evaluation was progression-free survival (PFS) and overall survival (OS). The PFS was defined as the time from treatment beginning to biochemical, and/or clinical/radiological progression (based on the results of CI examinations), last follow-up, or death from any cause, whichever occurred first. Castration-resistant prostate cancer (CRPC) was defined as castrating serum testosterone of < 50 ng/dL or 1.7 nmol/dL, and either biochemical progression (2 consecutive rises in PSA levels with 1 week apart, resulting in 25% increase over the nadir, with PSA > 2 ng/ml)16. The OS was defined as the time from treatment beginning to death from any cause or last follow-up, whichever occurred first. Statistical analysis Data for continuous variables are presented as the mean ± standard deviation or median (range) as appropriate, and categorical data are displayed as numbers (percentage). Univariate and multivariate Cox regression analyses performed to explore independent predictors of PFS and OS. Survival curves were generated using the Kaplan-Meier method and log-rank tests were used to compare the differences. The time-dependent of area under the ROC curve (AUC) were used to compare predictive accuracy. Statistical analysis was performed using PASW Statistics 18.0 (formerly SPSS, Chicago, IL, USA) and R i386 3.5.1 software were used to construct time-dependent AUC. All P values were 2-tailed and P < 0.05 was considered to be statistically significant. Results Baseline characteristics A total of 102 patients were finally included in this study according to the inclusion and exclusion criteria and the detailed clinicopathological characteristics of these patients were summarized in Table 1. Among 102 patients, 86 patients (84.3%) received ADT combined with abiraterone acetate, while 16 patients (15.7%) treated with ADT combined with enzalutamide. The median follow-up was 32.25 ± 14.51 months, and the interquartile range (IQR) of the median follow-up time was 21.00-38.75 months. 70 patients (68.63%) achieved a PSA90 response after treatment. Moreover, 61 patients (59.80%) progressed to CRPC and 48 patients (47.06%) died during the follow-up. The median nPSA was 0.20 (0.06, 11.71) ng/mL, and the mean time to nPSA was 10.82 ± 7.27 months. In addition, 55 patients (53.9%) had a PSA-D ≤ 0.08 at 3-months after treatment, while 47 patients (46.1%) had a PSA-D > 0.08. Table 1Baseline characteristic.VariableTotal (N = 102)Age, years (mean ± SD)71.12 ± 6.96iPSA, ng/mL (median, range)86.70 (41.58, 301.13)Biopsy Gleason score, n (%)6–728 (27.5%)838 (37.3%)9–1036 (35.3%)Clinical T stage, n (%)cT224 (23.5%)cT338 (37.3%)cT440 (39.2%)Clinical N stage, n (%)cN062 (60.8%)cN140 (39.2%)Non-regional lymph node metastases, n (%)41 (40.2%)Bone metastases, n (%)99 (97.1%)Visceral metastases, n (%)27 (26.48%)Treatment modality, n (%)ADT + Abiraterone acetate86 (84.3%)ADT + Enzalutamide16 (15.7%)nPSA, ng/mL (median, range)0.20 (0.06, 11.71)Time to nPSA, months (mean ± SD)10.82 ± 7.27PSA-D at 3-months, n (%)≤0.0855 (53.9%)>0.0847 (46.1%)PSA90 responders, n (%)70 (68.63%)CRPC during follow-up, n (%)61 (59.80%)Death during follow-up, n (%)48 (47.06%)Median Follow-up, months (mean ± SD)32.25 ± 14.51iPSA: initially prostate-specific antigen; SD: standard deviation; nPSA: nadir prostate-specific antigen; ADT: androgen deprivation therapy; PSA-D: prostate-specific antigen-density; PSA: prostate-specific antigen; CRPC: castration-resistant prostate cancer. Baseline characteristic. iPSA: initially prostate-specific antigen; SD: standard deviation; nPSA: nadir prostate-specific antigen; ADT: androgen deprivation therapy; PSA-D: prostate-specific antigen-density; PSA: prostate-specific antigen; CRPC: castration-resistant prostate cancer. Prognostic factors for PFS and OS Univariate Cox regression revealed that visceral metastases, nPSA, time to nPSA, PSA-D and PSA90 responders were associated with PFS (all P < 0.05) (Table 2). After reintegrating all of the above variable in the cox regression model, multivariate analysis suggested that nPSA ≤ 0.2 and PSA-D ≤ 0.08 were associated with better PFS (HR: 0.32; 95% CI: 0.13–0.77, P = 0.01; HR: 0.43; 95% CI: 0.23–0.83, P = 0.02). Moreover, the risk of diseases progression was increased nearly threefold in patients with visceral metastases (HR: 2.71; 95% CI: 1.48–4.95, P = 0.01). Table 2Univariate and multivariate Cox regression analyses of the clinicopathologic factors predict PFS.VariableUnivariableMultivariableHR95% CIPHR95% CIPAge (Continuous)1.020.98–1.060.26iPSA (Continuous)1.010.99–1.020.48Biopsy Gleason score8 vs.6–71.380.73–2.590.339–10 vs.6–71.190.61–2.330.61Clinical T stageT3 vs. T20.830.43–1.590.57T4 vs. T20.970.51–1.810.90Clinical N stage (N1 vs. N0)1.180.71–1.960.53Non-regional lymph node metastases (Presence vs. Absence)1.160.69–1.930.57Bone metastases (Presence vs. Absence)0.790.19–3.240.74Visceral metastases (Presence vs. Absence)6.693.79–11.830.012.711.48–4.950.01nPSA (> 0.2 vs. ≤0.2)0.130.07–0.250.010.320.13–0.770.01Time to nPSA (> 10 vs. ≤10)0.200.11–0.350.010.680.33–1.400.29PSA-D at 3-months (≤ 0.08 vs. >0.08)0.220.12–0.390.010.430.23–0.830.02PSA90 responders (No vs. Yes)4.992.94–8.470.011.510.81–2.810.19iPSA: initially prostate-specific antigen; nPSA: nadir prostate-specific antigen; PSA-D: prostate-specific antigen-density; PSA: prostate-specific antigen; PFS: progression-free survival. Univariate and multivariate Cox regression analyses of the clinicopathologic factors predict PFS. iPSA: initially prostate-specific antigen; nPSA: nadir prostate-specific antigen; PSA-D: prostate-specific antigen-density; PSA: prostate-specific antigen; PFS: progression-free survival. As shown in Table 3, univariate and multivariate Cox regression also indicted that the absence of visceral metastases, nPSA ≤ 0.2 and PSA-D ≤ 0.08 were independent prognostic factors for better OS in primary high-volume mHSPC patients treated with novel hormonal therapy agents (all P < 0.05). While, other factors including age, iPSA, biopsy Gleason score, clinical T and N stage, non-regional lymph node and bone metastases, time to nPSA and PSA90 responders were not associated with OS. Table 3Univariate and multivariate Cox regression analyses of the clinicopathologic factors predict OS.VariableUnivariableMultivariableHR95% CIPHR95% CIPAge (Continuous)1.020.98–1.070.25iPSA (Continuous)1.010.99–1.020.51Biopsy Gleason score8 vs.6–71.450.68–3.070.339–10 vs.6–71.930.91–4.080.09Clinical T stageT3 vs. T21.270.57–2.840.56T4 vs. T21.690.77–3.690.19Clinical N stage (N1 vs. N0)1.490.85–2.630.17Non-regional lymph node metastases (Presence vs. Absence)1.270.72–2.240.41Bone metastases (Presence vs. Absence)0.380.09–1.610.19Visceral metastases (Presence vs. Absence)8.214.51–14.950.012.041.10–3.800.03nPSA (> 0.2 vs. ≤0.2)0.030.01–0.110.010.060.01–0.290.01Time to nPSA (> 10 vs. ≤10)0.110.05–0.240.010.750.30–1.910.55PSA-D at 3-months (≤ 0.08 vs. >0.08)0.120.05–0.260.010.350.14–0.900.03PSA90 responders (No vs. Yes)5.693.12–10.400.010.870.45–1.680.68iPSA: initially prostate-specific antigen; nPSA: nadir prostate-specific antigen; PSA-D: prostate-specific antigen-density; PSA: prostate-specific antigen; OS: overall survival. Univariate and multivariate Cox regression analyses of the clinicopathologic factors predict OS. iPSA: initially prostate-specific antigen; nPSA: nadir prostate-specific antigen; PSA-D: prostate-specific antigen-density; PSA: prostate-specific antigen; OS: overall survival. Survival analysis Kaplan-Meier curves showed that the median PFS and OS in patients with visceral metastases was significantly shorter than those without visceral metastases (9 months vs. 28 months, HR: 5.31, 95%CI: 2.47–11.41, P < 0.01; 21 months vs. 35 months, HR: 7.27, 95%CI: 3.15–16.76, P < 0.01) (Fig. 1A and B). Compared with nPSA ≤ 0.2, nPSA > 0.2 were associated with worse PFS (12 months vs. 36 months, HR:6.82, 95%CI: 4.09–11.38, P < 0.01) and OS (25 months vs. 53 months, HR: 12.63, 95%CI: 6.83–23.37, P < 0.01) (Fig. 1C and D). Likewise, PSA-D > 0.08 at 3-months was also associated with worse PFS and OS. The median PFS and OS in patients who had PSA-D > 0.08 at 3-months were 12 months and 25 months, which was significantly shorter than those with PSA-D ≤ 0.08 (12 months vs. 33.5 months, HR: 4.88, HR: 2.89–8.22, P < 0.01; 25 months vs. 49 months, P < 0.01) (Fig. 1E and F). Kaplan‒Meier curve estimates of the time to progression-free survival (PFS) and overall survival (OS) in different group. (A). PFS of patients with and without visceral metastases. (B). OS of patients with and without visceral metastases. (C). PFS of patients in the different nadir prostate-specific antigen (nPSA) group. (D). OS of patients in the different nPSA group. (E). PFS of patients in the different PSA-density (PSA-D) group. (F). PFS of patients in the different PSA-D group. Exploratory analysis and predictive accuracy evaluation Based on the above findings, we divided 102 patients into four groups (Group 1: nPSA ≤ 0.2 and PSA-D ≤ 0.08; Group 2: nPSA ≤ 0.2 and PSA-D > 0.08; Group 3: nPSA > 0.2 and PSA-D ≤ 0.08; Group 4: nPSA > 0.2 and PSA-D > 0.08). Kaplan-Meier curves showed that patients with nPSA ≤ 0.2 and PSA-D ≤ 0.08 at 3-months had the best PFS and OS, while nPSA > 0.2 and PSA-D > 0.08 were associated with the worst PFS and OS (Fig. 2A and B). Kaplan-Meier curve estimates of the time to progression-free survival (PFS) and overall survival (OS). (A). PFS based on nadir prostate-specific antigen (nPSA) and PSA-density (PSA-D). (B). OS based on nPSA and PSA-D. Time-dependent AUC were used to evaluate the predictive accuracy of nPSA and PSA-D. As shown in Fig. 3A, the AUC values of the nPSA and PSA-D in predicting 20 months-PFS were 0.81, 0.78, respectively. The AUC values of the nPSA and PSA-D in predicting 30 months-OS were 0.85, 0.79, respectively (Fig. 3B). In addition, the combination of the nPSA and PSA-D had a better predictive accuracy for PFS and OS than nadir PSA or PSA-D alone. The time-dependent of AUC curves. Compare the accuracy of nadir prostate-specific antigen (nPSA), PSA-density (PSA-D) and the combination of these two factors in progression-free survival (PFS) (A) and overall survival (OS) (B) predicting. Discussion The landscape of therapy for high-volume mHSPC has changed in the past years and novel hormonal therapy agents combined with ADT is a new standard of care for high-volume mHSPC in clinical practice17. However, high-volume mHSPC is associated with poor outcomes as it has high risk to progress to castration-resistant diseases and not all high-volume mHSPC will response to novel hormonal therapy agents. The ability to predict who will response and identify prognostic biomarkers has raised great interest. In this study, we focused on the cohort of primary mHSPC treated with novel hormonal therapy agents and found that visceral metastases and PSA kinetics were independent prognostic factors, which might be helpful to guide personalized therapy decision-making in clinical practice. While, there were 28 patients (27.5%) had a GS of 6–7 in our study and the proportion was relatively high for a high-volume mHSPC cohort. But mostly of these patients had GS of 7 (10 patients (10/102, 9.80%) were GS 3 + 4 and 15 patients (15/102, 14.71%) were GS 4 + 3) and only 3 patients (3/102, 2.94%) had GS of 6. Owing to the tumor multifocality of PCa, the transrectal prostate biopsy might not accuracy to evaluate tumor grading, as mostly of PCa could experience upgrading after radical prostatectomy18–20, which might be the main reason for this phenomenon. Vesical metastases, an essential component of “high-volume” disease, is often considered the prognostically worst site for metastasis, resulting in the poorest outcome in mHSPC21–23. Roviello et al. performed a pooled analysis to explore the effect of novel hormonal therapy agents in mHSPC patients with visceral metastases. In their study, novel hormonal therapy agents, including abiraterone acetate, enzalutamide, apalutamide, could improve survival in mHSPC patients with visceral metastases than ADT alone24. Subsequently, Baciarello et al. also documented that compared with ADT alone, abiraterone acetate could significantly improve both PFS (HR: 0.527, 95%CI = 0.366–0.759, P = 0.0005) and OS (HR: 0.582, 95%CI: 0.406–0.835, P = 0.0029) in patients with mHSPC and visceral metastases25. Moreover, subgroup analysis found that patients with lung metastases could benefit more from the addition of abiraterone acetate than those with liver metastases. Nowadays, novel hormonal therapy agents or chemotherapy is the first-line treatment for patients with mHSPC and visceral metastases. However, in this present study, we found that visceral metastasis was an independent prognostic factor for primary mHSPC patients treated with novel hormonal therapy agents, and the risk of death was nearly 2-fold in patients with visceral metastases. In addition, patients with visceral metastases might be more easily to occur diseases progression compared with those without visceral metastases, as the risk of diseases progression increased nearly 3-fold. The main reason for this phenomenon was that visceral metastasis, especially for liver metastases, might be associated with a higher probability of neuroendocrine differentiation which might be more prone to obtain hormonal therapy resistance. Thus, we deduced that patients with mHSPC and visceral metastases could benefit more from the addition of chemotherapy and might be suitable candidates for triplet therapy. The goal of high-volume mHSPC management is to provide optimal outcomes by balancing the harm-to-benefit ration, and the patterns of PSA change may play a critical role in this process. Early studies have shown that the nPSA were a predictor of oncological outcomes in patients treated with ADT or chemotherapy8,26,27. Explorative analyses of the LATITUDE trial showed that high-risk mHSPC patients treated with abiraterone acetate were 6.1 times more likely to achieve a PSA value of ≤ 0.2 ng/mL than those treated with ADT alone, and patients with lower nPSA had a significantly lower risk of PFS and OS28. Subsequently, Sheng et al. also found that for mHSPC patients treated with abiraterone acetate, patients with PSA < 0.3ng/mL at 3-months had better castration-resistant free survival than those without PSA < 0.3ng/mL at 3-months (94.5% vs. 69.4%, P = 0.0004)29. To our best knowledge, this is first study to explore the prognostic role of PSA kinetics in high-volume mHSPC patients treated with novel hormonal therapy agents. In this present study, we found that the nPSA ≤ 0.2 ng/mL was independent prognostic factor for high-volume mHSPC patients treated with novel hormonal therapy agents. The median PFS and OS were 36 and 53 months which were significantly longer than those with nPSA > 0.2ng/mL. Furthermore, the AUC values of nPSA in predicting 20 months-PFS and 30 months-OS were 0.81, 0.85, respectively. Thus, nPSA might be an important prognostic factor in high-volume mHSPC patients treated with novel hormonal therapy agents. PSA-D, which correct the confounding effect of PSA production by the nonmalignant compartment, can accurately expose tumor-derived PSA kinetics and may be an approach to identify high-risk phenotypes30,31. Previously, several studies have documented that PSA-D > 0.08ng/mL2 reflected PSA produced in the prostate tumor microenvironment, which were associated with worse outcomes14,15,32.Recently, Greco et al. reviewed the data of 219 patients with localized prostate cancer and underwent stereotactic ablative radiotherapy, and pointed out that the persistence of high PSA-D levels at 3-months after treatment was associated with a significantly increased probability of long-term PSA relapse11. For primary high-volume mHSPC patients treated with novel hormonal therapy agents, we also noted that PSA-D at 3-months was also associated with PFS and OS and had remarkable accuracy in predicting 20 months-PFS and 30 months-OS, as the AUC values were 0.78 and 0.79, respectively. Furthermore, we also found that patients with nPSA ≤ 0.2 and PSA-D ≤ 0.08 had the best PFS and OS, and the combination of nPSA and PSA-D had a better predictive accuracy for survival outcomes than PSA-D or nPSA alone. Thus, we believed that for primary high-volume mHSPC, the change patterns of PSA during treatment could help urologists to identify very high-risk subgroup and develop more personalized treatment regimens. Despite with these positive results, there were several limitations of this study should be recognized. First, it was a retrospective study from a single center which might cause selection bias and information bias. While, in order to decrease potential biases in this study, we established a rigorous inclusion and exclusion criteria to minimize selection bias. In addition, we carefully reviewed and verified all data sources and double data entry and validation were also used in the data collections process to minimized information bias as much as possible. Second, only 102 patients were finally included in this present study, and the small sample size might limit the generalization of our results. Lastly, the prognostic value of nPSA and PSA-D was not externally validated. Hence, further prospective multicenter studies are needed to support our findings. In conclusion, we found that visceral metastases were associated with worse PFS and OS in primary high-volume mHSPC patients treated with novel hormonal therapy agents in this present study. The lower PSA-D at 3-months and nPSA after treatment were independent prognostic factors in primary high-volume mHSPC patients. In addition, the predictive effectiveness of the combination of nPSA and PSA-D on prognosis has advantages over nPSA or PSA-D alone. Thus, tracking PSA kinetics can alert urologists to potential progression and adjust treatment regimen at an earlier time point. Acknowledgements The authors appreciate Prof. Fengyan Yin from the Department of Urology, Baoji Central Hospital for helping with this paper. Author contributions Y.C.W., J.S., B.W., Q.L.M., D.C.W., H.B.J., T.L., X.H.L.,C.Q.W., X.H.L., Y.Q.J. and J.Z.L.wrote the main manuscript textY.C.W., J.S., J.J.F. prepared Figs. 1, 2 and 3All authors reviewed the manuscript. Funding This study was supported by the Natural Science Foundation in Shaanxi Province (S2022-YF-YBSF-1496 to JZL) and the Natural Science Foundation in Shaanxi Province (2023-JC-QN-0890 to JJF). Data availability The original contributions presented in the study are included in the article material. Further inquiries can be directed to the corresponding author. Declarations Competing interests The authors declare no competing interests. Ethics approval All procedures performed in the study and involving human participants were performed in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This retrospective analysis was approved by the Institutional Review Board of the Baoji Central Hospital, Baoji, Shaanxi, P.R. China. Patient consent statement Informed consent was obtained from all individual participants included in the study. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Yingchun Wang and Jie Suo contributed equally to this work. Contributor Information Junjie Fan, Email: 799042085@qq.com. Jianzhou Liu, Email: 13772693960@139.com. References Associated Data Data Availability Statement The original contributions presented in the study are included in the article material. Further inquiries can be directed to the corresponding author.